Day 1, Thursday, May 23rd | |
---|---|
08:30-10:00 | BCMA-targeted therapies in myeloma: the new treatment frontier Pre-COMy IME Symposium |
10:00-10:20 | Coffee Break |
10:20-10:30 | COMy 2024 kick-off |
10:30-12:00 | Session 1: Defining risk in myeloma |
12:00-12:30 | Lunch Break |
12:30-14:00 | To BCMA or not to BCMA? Addressing unanswered questions in RRMM Industry-supported Lunch Symposium by Johnson & Johnson |
14:00-14:10 | Technical Break |
14:10-15:35 | Session 2: Novel approaches for disease and response assessment |
15:35-15:45 | Technical Break |
15:45-17:15 | Is MRD ready for prime time for multiple myeloma patients? Industry-supported Symposium by Adaptive Biotechnologies |
17:15-17:30 | Coffee Break |
17:30-18:30 | Session 3: Precursor conditions and other plasma cell disorders |
18:30-19:15 | Session 4: Plenary lectures |
Day 2, Friday, May 24th | |
---|---|
08:15-08:30 | Good Morning Breakfast |
08:30-09:20 | Session 5: IMS Session |
09:20-09:30 | Technical Break |
09:30-11:00 | Harnessing the Immune System: New Emerging Data in Multiple Myeloma Industry-supported Symposium by BMS |
11:00-11:20 | Coffee Break |
11:20-12:30 | Session 6: Frontline management of newly diagnosed myeloma |
12:30-13:00 | Lunch Break |
13:00-14:30 | More choices, more flexibility: Individualising and optimising treatment in NDMM Industry-supported Lunch Symposium by Johnson & Johnson |
14:30-14:45 | Technical Break |
14:45-15:45 | Session 7: Practical management of specific situations |
15:45-16:00 | Coffee Break |
16:00-17:30 | Going for Gold: Making Strides in Multiple Myeloma Treatment Strategies Industry-supported Symposium by Sanofi |
17:30-17:45 | Technical Break |
17:45-18:45 | Session 8: Plenary lectures |
18:45-19:15 | COMy Award Ceremony |
Day 3, Saturday, May 25th | |
---|---|
08:00-08:10 | Good Morning Breakfast |
08:10-09:10 | Session 9: Novel agents under development |
09:10-09:20 | Technical Break |
09:20-10:50 | Is there a place for BCMA-based combinations in early RRMM? Industry-supported Symposium by GSK |
10:50-11:10 | Coffee Break |
11:10-12:30 | Session 10: How I treat a relapsed/refractory myeloma |
12:30-13:00 | Lunch Break |
13:00-14:00 | An innovative therapeutic option in the treatment of triple-class exposed relapsed refractory multiple myeloma (TCE RRMM) Industry-supported Lunch Symposium by Pfizer |
14:00-14:10 | Technical Break |
14:10-14:55 | Management of triple-class refractory patients in the absence of immunotherapies |
14:55-16:10 | Session 11: The road to cure: future protocols and directions |
16:10-16:30 | Coffee Break |
16:30-17:30 | Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms CME Symposium |
17:30-17:40 | Technical Break |
17:40-18:10 | Session 12: Plenary lecture |
18:10-18:20 | In-Person Conclusions |
Day 4 (ONLINE ONLY), Sunday, May 26th | |
---|---|
10:00-11:15 | Multiple Myeloma communications I |
11:15-11:30 | Short Break |
11:30-12:30 | Transforming Progress into Action in Relapsed/Refractory Multiple Myeloma: Improving Patient Outcomes Through Innovative Bispecific Antibodies Virtual CE Symposium |
12:30-13:45 | Mulitple Myeloma communications II |
13:45-14:15 | Final Panel Discussion and Conclusion |